Add-on therapies to metformin in type 2 diabetes: What modulates the respective decrements in postprandial and basal glucose?

Diabetes Technology and Therapeutics

Volumn 14, Issue 10, 2012, Pages 943-950

  Monnier, Louis ^a   Colette, Claude ^a   Comenducci, Andrea ^b   Vallée, Denis ^b   Dejager, Sylvie ^c  

^a UNIV MONTPELLIER   (France)

^b Glaxo Smith Kline Laboratories   (France)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; TREATMENT DURATION;

ADAMANTANE; ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BASAL METABOLISM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; POSTPRANDIAL PERIOD; PYRAZINES; PYRROLIDINES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 84867083079     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0045     Document Type: Article

References (32)

1. Krenz AJ, Bailey CJ: Oral antidiabetic agents: role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
2. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL: Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-399.
3. DeFronzo RA, Goodman AM; Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333: 541-549.
4. Stumvoll M, Nurjhan N, Periello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554.
5. Dunn CJ, Peters DH: Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-749.
6. Cusi K, DeFronzo RA: Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89-131.
7. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996;334: 574-583.
8. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-885.
9. Peter R, Dunseath G, Luzio SD, Chudleigh R, Choudhury SR, Owens DR: Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA1c in subjects with type 2 diabetes. Diabet Med 2009;26:974-980.
10. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
11. Ahrén B: Dipeptidyl peptidase-4 inhibitors. Clinical data and clinical implications. Diabetes Care 2007;30:1344-1350.
12. Peters A: Incretin-based therapies: review of current clinical trial data. Am J Med 2010;123:528-537.
13. Yki-Järvinen H: Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
14. Lebovitz HE: Insulin secretagogues: old and new. Diabetes Rev 1999;7:139-153.
15. Monnier L, Colette C, Owens D: Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther 2011;13(Suppl 1):S-25-S-32.
16. World Medical Association Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
17. Gorus F, Mathieu C, Gerlo E: How should HbA1c measurement be reported? Diabetologia 2006;49:7-10.
18. Sacks DB, Bruns DE, Goldstein DE, MacLaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement). Diabetes Care 2002; 25:750-786.
19. American Diabetes Association: Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl 1):S11-S61.
20. Dinneen S, Gerich JE, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:707-713.
21. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care 2007;30:263-269.
22. Monnier L, Wojtusciszyn A, Colette C, Owens D: The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011;13:813-818.
23. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32:193-203.
24. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A: Twelve and 52-week efficacy of the dipeptidyl peptide IV inhibitor LAF 237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:1874-1880.
25. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643.
26. UK Prospective Diabetes Study Group 16: Overview of 6 year's therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-1258.
27. DeFronzo RA, Tobin JD, Andres R: Glucose clamp: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
28. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
29. Lebovitz HE: Alphaglucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-145.
30. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
31. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI: Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010; 95:1566-1574.
32. Pozzilli P, Leslie RD, Chan J, DeFronzo R, Monnier L, Raz I, DelPrato S: The A1c and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010;26:239- 244.